Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05672420 | Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 181 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT05665075 | Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia | unknown | Phase 1 | 19 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 |
| clinicaltrials |
| NCT05665114 | Natural Killer(NK) Cell Therapy in r/r AML | unknown | Phase 1 | 18 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT04077866 | B7-H3 CAR-T for Recurrent or Refractory Glioblastoma | unknown | Phase 1 / Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT04385173 | Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma | unknown | Phase 1 | 12 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT05664906 | Evaluating Chinese Medicine Oral Rinse for Irradiated Oral Mucositis in Head & Neck Cancer Patients | unknown | Phase 1 / Phase 2 | 40 | Chinese University of Hong KongOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05663125 | LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas | unknown | Phase 1 / Phase 2 | 10 | Beijing Tiantan HospitalOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05654038 | A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 30 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT04612530 | PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer | unknown | Phase 1 | 18 | Amsterdam UMC, location VUmcOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05651100 | Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 50 | Kecellitics Biotech Company LtdINDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05557851 | Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas | unknown | Phase 1 | 36 | Minneamrita Therapeutics LLCINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05639179 | Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | unknown | Phase 1 / Phase 2 | 30 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05643417 | Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy | unknown | Phase 1 | 80 | Fudan UniversityOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT04433494 | A Study of TY-302 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | TYK Medicines, IncINDUSTRY | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05641233 | Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy(FIBROPANC-1) | unknown | Phase 1 / Phase 2 | 33 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT04100187 | Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia | unknown | Phase 1 | 100 | Kecellitics Biotech Company LtdINDUSTRY | 0 | Dec 1, 2022 | clinicaltrials |
| NCT05266768 | Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002# | unknown | Phase 1 | 36 | Chunrui LiOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT04503902 | Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 1 / Phase 2 | 46 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05625919 | A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa) | unknown | Phase 1 / Phase 2 | 54 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05622825 | Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers | unknown | Phase 1 / Phase 2 | 15 | National Taiwan University HospitalOTHER | 0 | Nov 21, 2022 | clinicaltrials |
| NCT05622227 | 68Ga PET/CT Imaging in Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT05620004 | Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy | unknown | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05620654 | A Phase I Dose-finding Trial of Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin | unknown | Phase 1 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 16, 2022 | clinicaltrials |
| NCT03664297 | Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor | unknown | Phase 1 | 86 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT04996771 | Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 88 | Sun Yat-sen UniversityOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05559008 | A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | unknown | Phase 1 / Phase 2 | 116 | Ruijin HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT05610202 | Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects | unknown | Phase 1 | 137 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 9, 2022 | clinicaltrials |
| NCT05608785 | Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes | unknown | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 0 | Nov 8, 2022 | clinicaltrials |
| NCT00100256 | Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 60 | Andarix PharmaceuticalsINDUSTRY | 1 | Nov 7, 2022 | clinicaltrials |
| NCT03855371 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS(PANDA-T0) | unknown | Phase 1 | 5 | Ruijin HospitalOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT00986661 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | unknown | Phase 1 | 78 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT03540017 | HIPEC After Initial CRS in Patients Who Have Received NACT | unknown | Phase 1 | 15 | Northwell HealthOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05603039 | A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 80 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02098512 | Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients | unknown | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05596266 | CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | Xuanwu Hospital, BeijingOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05497310 | Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL | unknown | Phase 1 / Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05135858 | Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma(METHOGLU) | unknown | Phase 1 | 18 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT03750071 | VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | unknown | Phase 1 / Phase 2 | 30 | Vaximm GmbHINDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05588206 | Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 21 | First People's Hospital of HangzhouOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05587088 | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)(PA001) | unknown | Phase 1 / Phase 2 | 82 | Hospital Universitario San IgnacioOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT04255576 | Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone | unknown | Phase 1 / Phase 2 | 139 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05027204 | A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | unknown | Phase 1 / Phase 2 | 94 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05577611 | An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | unknown | Phase 1 | 57 | Zhongnan HospitalOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT03825367 | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 13 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04118868 | Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma. | unknown | Phase 1 | 10 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05095441 | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | unknown | Phase 1 | 51 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jan 5, 2023source: clinicaltrials